Trial Profile
Study of Autologous T-cells Redirected to Mesothelin With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Mesothelin-CAR-T-cell-therapy-Shenzhen-BinDeBio (Primary) ; Cyclophosphamide
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Shenzhen BinDeBio
- 28 Aug 2018 New trial record